BlackRock’s Werewolf Therapeutics HOWL Stock Holding History
Bought
Maintained
Sold
Other funds holding HOWL
RCM
VCM
MB
LCM
SFM
DF
SCM
BlackRock's HOWL Position: Q1 2026 in Review
BlackRock reduced its Werewolf Therapeutics (HOWL) stake by 0.03% in Q1 2026, selling an estimated $24 and leaving 101,608 shares worth $84.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4996.
BlackRock first reported a position in HOWL in Q2 2021 and has held it in 20 quarters since. The position peaked at $15.2M in Q4 2021. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.
- BlackRock held 101,608 shares of Werewolf Therapeutics worth $84.6K as of Q1 2026.
- BlackRock sold 35 Werewolf Therapeutics shares in Q1 2026, an estimated $24.
- Werewolf Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4996 holding.
- BlackRock first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 20 quarters since.
- BlackRock's Werewolf Therapeutics position peaked at $15.2M in Q4 2021.
- 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.